MedTrace Logo

Ocular Changes With Alpha-2 Receptor Agonist.

NCT05670015 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-01-04

No results posted yet for this study

Summary

selective alpha-2 receptor agonists cause changes in intraocular pressure and pupillary size thus may affect patient quality of life.

Conditions

  • Glaucoma, Suspect
  • Aberration, Corneal Wavefront

Interventions

DRUG

Low dosage selective alpha-2 receptor agonists topical eyedrop

Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.

DRUG

High dosage selective alpha-2 receptor agonists topical eyedrop

Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ahmed A Abdelshafy, MD · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-08-10
Completion
2023-09-22

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05670015 on ClinicalTrials.gov